A number of firms have modified their ratings and price targets on shares of AstraZeneca plc (LON: AZN) recently:

  • 9/21/2016 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a GBX 5,800 ($75.71) price target on the stock.
  • 9/14/2016 – AstraZeneca plc was downgraded by analysts at BNP Paribas to a “neutral” rating. They now have a GBX 5,200 ($67.88) price target on the stock.
  • 9/14/2016 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Societe Generale. They now have a GBX 7,000 ($91.37) price target on the stock.
  • 9/13/2016 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 5,200 ($67.88) price target on the stock.
  • 9/12/2016 – AstraZeneca plc was upgraded by analysts at Jefferies Group from a “hold” rating to a “buy” rating. They now have a GBX 5,800 ($75.71) price target on the stock, up previously from GBX 5,400 ($70.49).
  • 9/8/2016 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Berenberg Bank. They now have a GBX 5,550 ($72.44) price target on the stock.
  • 9/8/2016 – AstraZeneca plc was given a new GBX 7,000 ($91.37) price target on by analysts at Societe Generale. They now have a “buy” rating on the stock.
  • 9/6/2016 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 5,800 ($75.71) price target on the stock.
  • 9/6/2016 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 9/6/2016 – AstraZeneca plc was given a new GBX 4,000 ($52.21) price target on by analysts at Goldman Sachs Group Inc.. They now have a “sell” rating on the stock.
  • 9/1/2016 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/25/2016 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Beaufort Securities.
  • 8/25/2016 – AstraZeneca plc was given a new GBX 5,550 ($72.44) price target on by analysts at Berenberg Bank. They now have a “buy” rating on the stock.
  • 8/25/2016 – AstraZeneca plc was given a new GBX 4,000 ($52.21) price target on by analysts at Goldman Sachs Group Inc.. They now have a “sell” rating on the stock.
  • 8/24/2016 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/23/2016 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a GBX 4,900 ($63.96) price target on the stock.
  • 8/19/2016 – AstraZeneca plc had its price target raised by analysts at Morgan Stanley from GBX 5,000 ($65.27) to GBX 5,800 ($75.71). They now have an “overweight” rating on the stock.
  • 8/16/2016 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a GBX 4,900 ($63.96) price target on the stock.
  • 8/11/2016 – AstraZeneca plc had its price target raised by analysts at Berenberg Bank from GBX 5,400 ($70.49) to GBX 5,600 ($73.10). They now have a “buy” rating on the stock.
  • 8/11/2016 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at HSBC. They now have a GBX 4,700 ($61.35) price target on the stock.
  • 8/10/2016 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Beaufort Securities.
  • 8/10/2016 – AstraZeneca plc was given a new GBX 4,000 ($52.21) price target on by analysts at Goldman Sachs Group Inc.. They now have a “sell” rating on the stock.
  • 8/9/2016 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/8/2016 – AstraZeneca plc was given a new GBX 5,400 ($70.49) price target on by analysts at Jefferies Group. They now have a “neutral” rating on the stock.
  • 8/8/2016 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 5,800 ($75.71) price target on the stock.
  • 8/8/2016 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a GBX 4,900 ($63.96) price target on the stock, up previously from GBX 4,800 ($62.66).
  • 8/4/2016 – AstraZeneca plc had its price target raised by analysts at Jefferies Group from GBX 4,800 ($62.66) to GBX 5,050 ($65.92). They now have a “hold” rating on the stock.
  • 8/2/2016 – AstraZeneca plc was given a new GBX 5,300 ($69.18) price target on by analysts at BNP Paribas. They now have a “buy” rating on the stock.
  • 8/2/2016 – AstraZeneca plc was given a new GBX 4,815 ($62.85) price target on by analysts at HSBC. They now have a “neutral” rating on the stock.
  • 7/29/2016 – AstraZeneca plc had its “underperform” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a GBX 4,000 ($52.21) price target on the stock.
  • 7/29/2016 – AstraZeneca plc had its “outperform” rating reaffirmed by analysts at BNP Paribas. They now have a GBX 5,000 ($65.27) price target on the stock.
  • 7/29/2016 – AstraZeneca plc was given a new GBX 5,168 ($67.46) price target on by analysts at Sanford C. Bernstein. They now have a “neutral” rating on the stock.
  • 7/29/2016 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Jefferies Group. They now have a GBX 4,800 ($62.66) price target on the stock.
  • 7/29/2016 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 5,800 ($75.71) price target on the stock.
  • 7/29/2016 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 7/29/2016 – AstraZeneca plc was given a new GBX 4,000 ($52.21) price target on by analysts at Goldman Sachs Group Inc.. They now have a “sell” rating on the stock.
  • 7/28/2016 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Bryan, Garnier & Co.
  • 7/27/2016 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 7/27/2016 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Citigroup Inc..

AstraZeneca plc (LON:AZN) opened at 5079.00 on Wednesday. The firm has a 50-day moving average price of GBX 5,021.00 and a 200-day moving average price of GBX 4,348.66. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The company’s market cap is GBX 64.25 billion.

The company also recently declared a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were given a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date was Thursday, August 11th. This represents a dividend yield of 1.37%.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.